RNA Editing of Israeli Founder Nonsense Mutations causing IRDs using Site-Directed Adenosine Deaminase Acting on RNA

Nina Schneider; Ricky Steinberg; Johanna Valensi; Amit Eylon; Eyal Banin; Erez Y. Levanon; Shay Ben-Aroya; Dror Sharon

RNA Editing of Israeli Founder Nonsense Mutations causing IRDs using Site-Directed Adenosine Deaminase Acting on RNA

Nina Schneider, Ricky Steinberg, Johanna Valensi, Amit Eylon, Eyal Banin, Erez Y. Levanon, Shay Ben-Aroya, Dror Sharon

The Mina and Everard Goodman Faculty of Life Sciences - at Bar-Ilan University

Bar-Ilan University

Research output: Contribution to journal › Meeting Abstract › peer-review

Abstract

Purpose: Targeted RNA editing utilizing the ubiquitous human adenosine deaminase acting on RNA (ADAR) enzyme is a possible new genetic therapeutic approach for the treatment of inherited retinal diseases (IRDs). Utilizing guideRNA (gRNA) to recruit the endogenously expressed ADAR enzyme to a mutated RNA and facilitating the deaminization of a specific adenosine to inosine (read as a guanine by the ribosome), allows for the correction of mRNA transcripts in a transient and tunable manner. According to our recent analyses, 40% of single nucleotide variants (SNVs)-causing IRDs are candidates for ADAR-directed editing. Our aim is to design and test gRNAs that induce targeted ADAR editing for 3 common Israeli mutations causing IRDs: TRPM1-p. K294*, FAM161A-p. R523*, and KIZ-p. R76*.

Original language	English
Pages (from-to)	58 – A0031
Journal	Investigative Ophthalmology and Visual Science
Volume	63
Issue number	7
State	Published - 1 Jun 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

https://iovs.arvojournals.org/article.aspx?articleid=2778932

Cite this

@article{75311765002e43e1bc4404fbc2bb9069,

title = "RNA Editing of Israeli Founder Nonsense Mutations causing IRDs using Site-Directed Adenosine Deaminase Acting on RNA",

abstract = "Purpose: Targeted RNA editing utilizing the ubiquitous human adenosine deaminase acting on RNA (ADAR) enzyme is a possible new genetic therapeutic approach for the treatment of inherited retinal diseases (IRDs). Utilizing guideRNA (gRNA) to recruit the endogenously expressed ADAR enzyme to a mutated RNA and facilitating the deaminization of a specific adenosine to inosine (read as a guanine by the ribosome), allows for the correction of mRNA transcripts in a transient and tunable manner. According to our recent analyses, 40\% of single nucleotide variants (SNVs)-causing IRDs are candidates for ADAR-directed editing. Our aim is to design and test gRNAs that induce targeted ADAR editing for 3 common Israeli mutations causing IRDs: TRPM1-p. K294*, FAM161A-p. R523*, and KIZ-p. R76*.",

author = "Nina Schneider and Ricky Steinberg and Johanna Valensi and Amit Eylon and Eyal Banin and Levanon, \{Erez Y.\} and Shay Ben-Aroya and Dror Sharon",

year = "2022",

month = jun,

day = "1",

language = "الإنجليزيّة",

volume = "63",

pages = "58 – A0031",

journal = "Investigative Ophthalmology and Visual Science",

issn = "0146-0404",

publisher = "Association for Research in Vision and Ophthalmology Inc.",

number = "7",

}

TY - JOUR

T1 - RNA Editing of Israeli Founder Nonsense Mutations causing IRDs using Site-Directed Adenosine Deaminase Acting on RNA

AU - Schneider, Nina

AU - Steinberg, Ricky

AU - Valensi, Johanna

AU - Eylon, Amit

AU - Banin, Eyal

AU - Levanon, Erez Y.

AU - Ben-Aroya, Shay

AU - Sharon, Dror

PY - 2022/6/1

Y1 - 2022/6/1

N2 - Purpose: Targeted RNA editing utilizing the ubiquitous human adenosine deaminase acting on RNA (ADAR) enzyme is a possible new genetic therapeutic approach for the treatment of inherited retinal diseases (IRDs). Utilizing guideRNA (gRNA) to recruit the endogenously expressed ADAR enzyme to a mutated RNA and facilitating the deaminization of a specific adenosine to inosine (read as a guanine by the ribosome), allows for the correction of mRNA transcripts in a transient and tunable manner. According to our recent analyses, 40% of single nucleotide variants (SNVs)-causing IRDs are candidates for ADAR-directed editing. Our aim is to design and test gRNAs that induce targeted ADAR editing for 3 common Israeli mutations causing IRDs: TRPM1-p. K294*, FAM161A-p. R523*, and KIZ-p. R76*.

AB - Purpose: Targeted RNA editing utilizing the ubiquitous human adenosine deaminase acting on RNA (ADAR) enzyme is a possible new genetic therapeutic approach for the treatment of inherited retinal diseases (IRDs). Utilizing guideRNA (gRNA) to recruit the endogenously expressed ADAR enzyme to a mutated RNA and facilitating the deaminization of a specific adenosine to inosine (read as a guanine by the ribosome), allows for the correction of mRNA transcripts in a transient and tunable manner. According to our recent analyses, 40% of single nucleotide variants (SNVs)-causing IRDs are candidates for ADAR-directed editing. Our aim is to design and test gRNAs that induce targeted ADAR editing for 3 common Israeli mutations causing IRDs: TRPM1-p. K294*, FAM161A-p. R523*, and KIZ-p. R76*.

UR - https://scholar.google.com/citations?view_op=view_citation&hl=en&user=ItOvQJ4AAAAJ&sortby=pubdate&citation_for_view=ItOvQJ4AAAAJ%3AML0RJ9NH7IQC&inst=1200643855431153338

M3 - موجز برنامج المؤتمر

SN - 0146-0404

VL - 63

SP - 58 – A0031

JO - Investigative Ophthalmology and Visual Science

JF - Investigative Ophthalmology and Visual Science

IS - 7

ER -

RNA Editing of Israeli Founder Nonsense Mutations causing IRDs using Site-Directed Adenosine Deaminase Acting on RNA

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this